Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

nelotanserin

Known as: 1-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-3-(2,4-Difluorophenyl)Urea, Urea, N-(3-(4-Bromo-1-Methyl-1H-Pyrazol-5-yl)-4-Methoxyphenyl)-N'-(2,4-Difluorophenyl)- 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
G protein-coupled receptors (GPCRs), also known as 7-transmembrane receptors, are the single largest class of drug targets… Expand
2018
2018
Several agents have been shown to improve sleep induction and/or maintenance in patients with primary or comorbid insomnia. These… Expand
2018
2018
  • H. Mucke
  • Assay and drug development technologies
  • 2018
  • Corpus ID: 51679430
 
Review
2017
Review
2017
Objective: To evaluate the safety and efficacy of nelotanserin in Lewy body dementia subjects experiencing visual hallucinations… Expand
Review
2017
Review
2017
This article reviews current treatment strategies and recent advances for the Lewy body dementias (LBDs). Current available… Expand
  • table 1
  • figure 1
  • table 2
Review
2017
Review
2017
Several drug classes are widely prescribed when difficulties with sleep induction or sleep maintenance occur, as is the case in… Expand
Review
2011
Review
2011
  • J. Monti
  • Sleep medicine reviews
  • 2011
  • Corpus ID: 29773003
Based on electrophysiological, neurochemical, genetic and neuropharmacological approaches, it is currently accepted that… Expand
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
2010
2010
5-Hydroxytryptamine (5-HT)2A receptor inverse agonists are promising therapeutic agents for the treatment of sleep maintenance… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • table 2
2010
2010
Insomnia affects a growing portion of the adult population in the U.S. Most current therapeutic approaches to insomnia primarily… Expand